DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak Et Al USOO9642912B2 (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak et al. (45) Date of Patent: *May 9, 2017 (54) TOPICAL FORMULATIONS FOR TREATING (58) Field of Classification Search SKIN CONDITIONS CPC ...................................................... A61K 31f S7 (71) Applicant: Crescita Therapeutics Inc., USPC .......................................................... 514/171 Mississauga (CA) See application file for complete search history. (72) Inventors: Edward T. Kisak, San Diego, CA (56) References Cited (US); John M. Newsam, La Jolla, CA (US); Dominic King-Smith, San Diego, U.S. PATENT DOCUMENTS CA (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Santa Barbara, 5,602,183 A 2f1997 Martin et al. CA (US); Wade A. Hull, Kaysville, UT 5,648,380 A 7, 1997 Martin 5,874.479 A 2, 1999 Martin (US); Ngoc Truc-ChiVo, Longueuil 6,328,979 B1 12/2001 Yamashita et al. (CA) 7,001,592 B1 2/2006 Traynor et al. 7,795,309 B2 9/2010 Kisak et al. (73) Assignee: Crescita Therapeutics Inc., 8,343,962 B2 1/2013 Kisak et al. Mississauga (CA) 8,513,304 B2 8, 2013 Kisak et al. 8,535,692 B2 9/2013 Pongpeerapat et al. (*) Notice: Subject to any disclaimer, the term of this 9,308,181 B2* 4/2016 Kisak ..................... A61K 47/12 patent is extended or adjusted under 35 2002fOOO6435 A1 1/2002 Samuels et al. 2002fOO64524 A1 5, 2002 Cevc U.S.C. 154(b) by 204 days. 2005, OO 14823 A1 1/2005 Soderlund et al. This patent is Subject to a terminal dis 2005.00754O7 A1 4/2005 Tamarkin et al. claimer. 2005, 0196354 A1 9/2005 Soshinsky 2006/0229.364 A1 10/2006 Hobbs et al. (21) Appl. No.: 14/578,812 2008.0075793 A1 3/2008 Dunshee et al. 2011 0028460 A1 2/2011 Kisak et al. (22) Filed: Dec. 22, 2014 2013, OO79371 A1 3/2013 Sundberg et al. 2013,00794.04 A1 3/2013 Kisak et al. (65) Prior Publication Data 2013/O165504 A1 6/2013 Bancel et al. 2013/02599.24 A1 10/2013 Bancel et al. US 2015/0297723 A1 Oct. 22, 2015 FOREIGN PATENT DOCUMENTS Related U.S. Application Data GB 2008.946 6, 1979 (63) Continuation-in-part of application No. 13/791,460, WO WO 96/33706 10, 1996 filed on Mar. 8, 2013, now Pat. No. 9,308,181, which WO WO 2005/OO951O 2, 2005 is a continuation-in-part of application No. (Continued) 13/680,623, filed on Nov. 19, 2012, now Pat. No. 8,513.304, which is a continuation of application No. OTHER PUBLICATIONS 12/848,792, filed on Aug. 2, 2010, now Pat. No. 8.343.962, which is a continuation-in-part of PCT Application No. PCT/CA2014/051049: Filing date Oct. 31, application No. 12/281.561, filed as application No. 2014: Nuvo Research Inc.; International Search Report mailed Feb. PCT/IB2007/001983 on Mar. 6, 2007, now Pat. No. 10, 2015. 7,795,309. (Continued) (60) Provisional application No. 60/778,847, filed on Mar. 6, 2006. Primary Examiner — Raymond Henley, III (51) Int. Cl. (74) Attorney, Agent, or Firm — Thorpe North & A6 IK3I/56 (2006.01) Western, LLP A6 IK 47/8 (2017.01) A 6LX 3/573 (2006.01) A6 IK 47/4 (2017.01) (57) ABSTRACT A6 IK 47/12 (2006.01) A6 IK 9/00 (2006.01) The present disclosure is drawn to topical formulations and A6 IK 47/20 (2006.01) related methods. In one embodiment, a topical formulation A6 IK 9/06 (2006.01) is provided that includes at least one corticosteroid, a first A6DF 7/03 (2006.01) compound, and a second compound. The first compound and A6.1 F 7/O2 (2006.01) second compound are different and each is selected from the (52) U.S. Cl. group consisting of N-lauroyl sarcosine, sodium octyl Sul CPC .............. A61K 47/183 (2013.01); A61F 7/03 fate, methyl laurate, isopropyl myristate, oleic acid, glyceryl (2013.01); A61K 9/0014 (2013.01); A61K 9/06 oleate, and Sodium lauryl Sulfoacetate. (2013.01); A61 K3I/573 (2013.01); A61 K 47/12 (2013.01); A61K 47/14 (2013.01); A61 K 47/20 (2013.01); A61F 2007/0261 (2013.01) 46 Claims, 4 Drawing Sheets US 9,642.912 B2 Page 2 (56) References Cited FOREIGN PATENT DOCUMENTS WO WO 2005/O18530 3, 2005 WO WO 2013,106496 T 2013 OTHER PUBLICATIONS Teixeira, et al., “Local anesthetic-induced microscopic and mesoscopic effects in micelles. A fluorescence, spin label and SAXS”; 2001 Biochimica et Biophysica; ACTA 1510 (2001) pp. 93-105. * cited by examiner U.S. Patent May 9, 2017 Sheet 1 of 4 US 9,642,912 B2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - OControl iF1 AF2 i)CF3 & seF4 F5 & iOF6 4.7O AF8 4.60 i. sEF10 to F11 U.S. Patent May 9, 2017 Sheet 2 of 4 US 9,642,912 B2 F1-F9 Viscosity 7.00 to Control HF1 CF3 e iF4 8 OF5 s OF6 AF8 tF10 IOF11 O.OO iososo. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - G Time Zero Month 1 Month 2 Month 3 U.S. Patent May 9, 2017 Sheet 3 of 4 US 9,642,912 B2 O Control F1 sF2 F3 a 64 i OF5 CF6 F7 iAF8 U.S. Patent May 9, 2017 Sheet 4 of 4 US 9,642,912 B2 F1-F9 Permeation Durapore Membrane 7000 sex 6OOO i s O Control 5 O O O . F1 F2 toe F3 sep F4 D F5 HF7 sF10 OF11 US 9,642,912 B2 1. 2 TOPCAL FORMULATIONS FOR TREATING molecules across the skin by, for example, disrupting the SKIN CONDITIONS lipid bilayers of the stratum corneum. Over 300 Substances have been identified as MPETMs but This application is a continuation-in-part of U.S. patent surprisingly few have been successfully developed into application Ser. No. 13/791,460 filed on Mar. 8, 2013 and commercial formulations. Many potent MPETMs are irritat issued as U.S. Patent No. 9.308,181, which is a continua ing to the cells of the epidermis which can limit both the tion-in-part of U.S. patent application Ser. No. 13/680,623. choice and concentration of MPETMs suitable for topical filed Nov. 19, 2012 and issued as U.S. Pat. No. 8,513,304, formulations. Discovery of new MPETMs to increase skin which was a continuation of U.S. patent application Ser. No. permeability is a highly desirable area and has had high 12/848,792, filed Aug. 2, 2010 and issued as U.S. Pat. No. 10 activity over the last 30 years. However, the number of 8.343.962, which was a continuation-in-part of U.S. patent substances identified to be penetration enhancers is still application Ser. No. 12/281.561, filed on Jan. 12, 2009 and relatively small when considering the more than 25,000,000 issued as U.S. Pat. No. 7,795,309, which was a national substances identified in the CAS registry (Chemical stage of PCT/IB2007/001983 filed on Mar. 6, 2007, which 15 Abstracts Service, Columbus, Ohio, www.cas.org). The claimed priority to U.S. Provisional Application Ser. No. number of candidate drugs suitable for topical and transder 60/788,847, each of which is incorporated herein by refer mal administration could be significantly increased with CCC. improved penetration enhancers. BACKGROUND SUMMARY Topical formulations for application to the skin can be With this background in mind, the present disclosure is useful in cosmetic applications, for treating conditions of the drawn to topical formulationstransdermal systems, and upper skin layers, and for transdermal administration of methods for treating skin conditions. In one embodiment, a active agents to the local tissue underlying the skin or into 25 topical formulation is provided that comprises (i) at least one the blood for systemic distribution. For example, using a corticosteroid, (ii) a first compound, and (iii) a second topical formulation of a pharmaceutical agent is advanta compound. The first compound and second compound are geous because it can avoid first-pass metabolism, circum different and each is selected from the group consisting of vent gastrointestinal (“GI) absorption, allow delivery of an N-lauroyl sarcosine, Sodium octyl sulfate, methyl laurate, active ingredient with a relatively short biological half-life 30 isopropyl myristate, oleic acid, glyceryl oleate, and sodium and/or a narrow therapeutic window, and facilitate uniform lauryl Sulfoacetate. plasma dosing of the active ingredient, and/or can improve In another embodiment, a method of treating a skin user compliance. condition Such as psoriasis or dermatitis can comprise In spite of the advantages, transdermal administration is topical or transdermal administration of a corticosteroid to a usually limited to about a dozen Small lipophilic drugs, 35 Subject. The formulation can comprise at least one corticos available in transdermal patch format (including scopol teroid, a first compound, and a second compound. The first amine, fentanyl, estradiol, nitroglycerine, nicotine, and tes compound and second compound are different and each is tosterone). Skin has evolved to impede the flux of exogenous selected from the group consisting of N-lauroyl sarcosine, molecules so as to provide a strong barrier to molecular Sodium octyl sulfate, methyl laurate, isopropyl myristate, delivery, particularly agents such as pharmaceutical agents. 40 oleic acid, glyceryl oleate, and sodium lauryl Sulfoacetate. In Transdermal drug administration is difficult because skin is one embodiment, the first and second compound can an excellent diffusion barrier. improve the flux and/or stability of the topical formulation Structurally, the skin consists of two principal parts: (i) a when compared to a comparative formulation devoid of the relatively thin outermost layer (the “epidermis'), and (ii) a first compound and the second compound and replaced with thicker inner region (the “dermis).
Load more

Recommended publications
  • Report of the Advisory Group to Recommend Priorities for the IARC Monographs During 2020–2024
    IARC Monographs on the Identification of Carcinogenic Hazards to Humans Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 CONTENTS Introduction ................................................................................................................................... 1 Acetaldehyde (CAS No. 75-07-0) ................................................................................................. 3 Acrolein (CAS No. 107-02-8) ....................................................................................................... 4 Acrylamide (CAS No. 79-06-1) .................................................................................................... 5 Acrylonitrile (CAS No. 107-13-1) ................................................................................................ 6 Aflatoxins (CAS No. 1402-68-2) .................................................................................................. 8 Air pollutants and underlying mechanisms for breast cancer ....................................................... 9 Airborne gram-negative bacterial endotoxins ............................................................................. 10 Alachlor (chloroacetanilide herbicide) (CAS No. 15972-60-8) .................................................. 10 Aluminium (CAS No. 7429-90-5) .............................................................................................. 11
    [Show full text]
  • Natural Thiopeptides As a Privileged Scaffold for Drug Discovery and Therapeutic Development
    – MEDICINAL Medicinal Chemistry Research (2019) 28:1063 1098 CHEMISTRY https://doi.org/10.1007/s00044-019-02361-1 RESEARCH REVIEW ARTICLE Natural thiopeptides as a privileged scaffold for drug discovery and therapeutic development 1 1 1 1 1 Xiaoqi Shen ● Muhammad Mustafa ● Yanyang Chen ● Yingying Cao ● Jiangtao Gao Received: 6 November 2018 / Accepted: 16 May 2019 / Published online: 29 May 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Since the start of the 21st century, antibiotic drug discovery and development from natural products has experienced a certain renaissance. Currently, basic scientific research in chemistry and biology of natural products has finally borne fruit for natural product-derived antibiotics drug discovery. A batch of new antibiotic scaffolds were approved for commercial use, including oxazolidinones (linezolid, 2000), lipopeptides (daptomycin, 2003), and mutilins (retapamulin, 2007). Here, we reviewed the thiazolyl peptides (thiopeptides), an ever-expanding family of antibiotics produced by Gram-positive bacteria that have attracted the interest of many research groups thanks to their novel chemical structures and outstanding biological profiles. All members of this family of natural products share their central azole substituted nitrogen-containing six-membered ring and are fi 1234567890();,: 1234567890();,: classi ed into different series. Most of the thiopeptides show nanomolar potencies for a variety of Gram-positive bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and penicillin-resistant Streptococcus pneumonia (PRSP). They also show other interesting properties such as antiplasmodial and anticancer activities. The chemistry and biology of thiopeptides has gathered the attention of many research groups, who have carried out many efforts towards the study of their structure, biological function, and biosynthetic origin.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak Et Al
    US008343962B2 (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak et al. (45) Date of Patent: *Jan. 1, 2013 (54) TOPICAL FORMULATION (58) Field of Classi?cation Search ............. .. 514/226.5, 514/334, 420, 557, 567 (75) Inventors: Edward T. Kisak, San Diego, CA (US); See application ?le fOr Complete Search history. John M. NeWsam, La Jolla, CA (US); _ Dominic King-Smith, San Diego, CA (56) References C‘ted (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Goleta, CA (US) US' PATENT DOCUMENTS 5,602,183 A 2/1997 Martin et al. (73) Assignee: NuvoResearchOntano (CA) Inc., Mississagua, 6,328,979 2B1 12/2001 Yamashita et a1. 7,001,592 B1 2/2006 Traynor et a1. ( * ) Notice: Subject to any disclaimer, the term of this 7,795,309 B2 9/2010 Kisak eta1~ patent is extended or adjusted under 35 2002/0064524 A1 5/2002 Cevc U.S.C. 154(b) by 212 days. FOREIGN PATENT DOCUMENTS This patent is subject to a terminal dis- W0 WO 2005/009510 2/2005 claimer- OTHER PUBLICATIONS (21) APPI' NO‘, 12/848,792 International Search Report issued on Aug. 8, 2008 in application No. PCT/lB2007/0l983 (corresponding to US 7,795,309). _ Notice ofAlloWance issued on Apr. 29, 2010 by the Examiner in US. (22) Med Aug- 2’ 2010 Appl. No. 12/281,561 (US 7,795,309). _ _ _ Of?ce Action issued on Dec. 30, 2009 by the Examiner in US. Appl. (65) Prior Publication Data No, 12/281,561 (Us 7,795,309), Us 2011/0028460 A1 Feb‘ 3’ 2011 Primary Examiner * Raymond Henley, 111 Related U 5 Application Data (74) Attorney, Agent, or Firm * Foley & Lardner LLP (63) Continuation-in-part of application No.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Carboxylic Acid Derivates
    Europaisches Patentamt 0 367 484 J> European Patent Office CO Publication number: A1 Office europeen des brevets © EUROPEAN PATENT APPLICATION A61K 31/29 © Application number: 89310994.2 © int. ci.5: C07D 233/64 , C07D 277/42 C07D 277/28 @ Date of filing: 25.10.89 C07D 295/08 C07D 249/14 C07D 211/20 C07D 417/04 © Priority: 26.10.88 GB 8825058 © Applicant: GLAXO GROUP LIMITED 26.06.89 GB 8914631 Clarges House 6-12 Clarges Street London W1Y8DH(GB) © Date of publication of application: 09.05.90 Bulletin 90/19 © Inventor: Clitherow, John Watson 54, Gilders © Designated Contracting States: Sawbridgeworth Hertfordshire(GB) AT BE CH DE ES FR GB GR IT LI LU NL SE © Representative: Marchant, James Ian et al Elkington and Fife Beacon House 113 Kingsway London WC2B 6PP(GB) © Carboxylic acid derivates. © The invention relates to salts formed between basic H2-receptor antagonists and a complex of bismuth with a carboxylic acid, and solvate of such salts, excluding salts in which the basic H2-receptor antagonist is ranitidine. Examples of suitable carboxylic acids are citric acid and tartaric acid. Examples of basic rVreceptor antagonists are cimetidine, sufotidine famotidine and nizatidine. The salts ares useful in the treatment of gastrointestinal disorders, particularly gastroduodenal conditions. The salts show the antisecretory activity associated with the basic H2-receptor antagonist together with antibacterial activity against Campylobacter pylori and they also possess cytoprotective properties. 00 (0 a. LU Xerox Copy Centre EP 0 367 484 A1 CARBOXYLIC ACID DERIVATIVES This invention relates to salts of compounds having antagonist activity at histamine H2- receptors, to a process for the preparation thereof, to pharmaceutical compositions containing them and to their use in therapeutics.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Identification of Compounds That Rescue Otic and Myelination
    RESEARCH ARTICLE Identification of compounds that rescue otic and myelination defects in the zebrafish adgrg6 (gpr126) mutant Elvira Diamantopoulou1†, Sarah Baxendale1†, Antonio de la Vega de Leo´ n2, Anzar Asad1, Celia J Holdsworth1, Leila Abbas1, Valerie J Gillet2, Giselle R Wiggin3, Tanya T Whitfield1* 1Bateson Centre and Department of Biomedical Science, University of Sheffield, Sheffield, United Kingdom; 2Information School, University of Sheffield, Sheffield, United Kingdom; 3Sosei Heptares, Cambridge, United Kingdom Abstract Adgrg6 (Gpr126) is an adhesion class G protein-coupled receptor with a conserved role in myelination of the peripheral nervous system. In the zebrafish, mutation of adgrg6 also results in defects in the inner ear: otic tissue fails to down-regulate versican gene expression and morphogenesis is disrupted. We have designed a whole-animal screen that tests for rescue of both up- and down-regulated gene expression in mutant embryos, together with analysis of weak and strong alleles. From a screen of 3120 structurally diverse compounds, we have identified 68 that reduce versican b expression in the adgrg6 mutant ear, 41 of which also restore myelin basic protein gene expression in Schwann cells of mutant embryos. Nineteen compounds unable to rescue a strong adgrg6 allele provide candidates for molecules that may interact directly with the Adgrg6 receptor. Our pipeline provides a powerful approach for identifying compounds that modulate GPCR activity, with potential impact for future drug design. DOI: https://doi.org/10.7554/eLife.44889.001 *For correspondence: [email protected] †These authors contributed Introduction equally to this work Adgrg6 (Gpr126) is an adhesion (B2) class G protein-coupled receptor (aGPCR) with conserved roles in myelination of the vertebrate peripheral nervous system (PNS) (reviewed in Langenhan et al., Competing interest: See 2016; Patra et al., 2014).
    [Show full text]
  • Drug Antioxidant Effects a Basis for Drug Selection?
    REVIEW ARTI LE Drugs 42 (4): 569-605, 1991 00 12-6667/ 91/ 00 I0-0569/ $ 18.50/0 © Adis International Limited. All rights reserved. DRU161 Drug Antioxidant Effects A Basis for Drug Selection? Barry Halliwell Pulmonary Medicine, UC Davis Medical Center, Sacramento , California, USA Contents 570 Summary 570 I. What is a Free Radical? 570 1.1 Definition of a Free Radical 57/ 1.2 Hydroxyl Radical 572 1.3 Formation of Oxygen Radicals In Vivo 574 1.4 Reactive Oxygen Species 575 1.5 Transition Metal Ions and Free Radical Reactions 575 1.6 Antioxidant Defence In Vivo: Intracellular 576 1.7 Antioxidant Defence In Vivo: Extracellular 579 2. Free Radical Damage to Cells and the Protective Ability of Antioxidants 579 2.1 Mechanisms of Cell Damage: The Molecular Targets 58/ 2.2 How to Characterise an Antioxidant 5 2 3. The Role of Free Radicals in Human Disease 582 3.1 Causation of Disease 582 3.2 A Significant Consequence of Disease Pathology 584 3.3 A General Consequence of Tissue Injury 585 3.4 What Can We Expect from Antioxidant Therapy? 586 586 4. Antioxidants in Disease Therapy 586 4.1 Use of Naturally Occurring Antioxidants and Derived Compounds 587 4.1.1 Superoxide Dismutase 587 4.1.2 Superoxide Dismutase 'Mimics' 588 4.1.3 a-Tocopherol 589 4.1.4 Ascorbic Acid (Vitamin C) 589 4.1.5 Adenosine 589 4.1.6 Lactoferrin 590 4.1.7 Nicotinamide 59/ 4.1.8 Glutathione and its Precursors 59/ 4.1.9 Carotenoids 59/ 4.2 'Synthetic' Antioxidants 59/ 4.2.1 Mercaptopropionylglycine and Other Thiols 592 4.2.2 Ebselen: A Glutathione Peroxidase Mimic? 593 4.2.3 Allopurinol, Oxypurinol and Other Xanth ine Oxidase Inhibitors 593 4.2.4 Inhibitors of the Generation of Reactive Oxygen Species by Phagocytes 595 4.2.5 Chelating Agents: Deferoxamine 595 4.2.6 Other Iron Chelators: Hydroxypyridones 596 4.2.7 Other Iron Chelators: ICRF-187 and the 'Lazaroids' 4.2.8 Probucol and Other Chain-Breaking Antioxidants 570 Drugs 42 (4) 1991 596 5.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • Review Article
    Free Radical Biology & Medicine, Vol. 33, No. 6, pp. 774–797, 2002 Copyright © 2002 Elsevier Science Inc. Printed in the USA. All rights reserved 0891-5849/02/$–see front matter PII S0891-5849(02)00956-5 Review Article STRUCTURE AND FUNCTION OF XANTHINE OXIDOREDUCTASE: WHERE ARE WE NOW? ROGER HARRISON Department of Biology and Biochemistry, University of Bath, Bath, UK (Received 11 February 2002; Accepted 16 May 2002) Abstract—Xanthine oxidoreductase (XOR) is a complex molybdoflavoenzyme, present in milk and many other tissues, which has been studied for over 100 years. While it is generally recognized as a key enzyme in purine catabolism, its structural complexity and specialized tissue distribution suggest other functions that have never been fully identified. The publication, just over 20 years ago, of a hypothesis implicating XOR in ischemia-reperfusion injury focused research attention on the enzyme and its ability to generate reactive oxygen species (ROS). Since that time a great deal more information has been obtained concerning the tissue distribution, structure, and enzymology of XOR, particularly the human enzyme. XOR is subject to both pre- and post-translational control by a range of mechanisms in response to hormones, cytokines, and oxygen tension. Of special interest has been the finding that XOR can catalyze the reduction of nitrates and nitrites to nitric oxide (NO), acting as a source of both NO and peroxynitrite. The concept of a widely distributed and highly regulated enzyme capable of generating both ROS and NO is intriguing in both physiological and pathological contexts. The details of these recent findings, their pathophysiological implications, and the requirements for future research are addressed in this review.
    [Show full text]
  • Download (PDF 277.63
    PROJECT REVIEW “Characterization of the main metabolites of 17-methylstenblone and 17 methylmethenolone produced by human hepatocytes and liver fractions” Prof C. Ayotte, (INRS-Institut Armand-Frappier, Canada) New steroids openly appear on the market in products labelled with a rather confusing nomenclature. Once characterized, pharmaceutical grade products not being available, knowledge of the biotransformation pathways essential to an efficient detection of utilization by athletes is difficult to gain since administration to human volunteers should be restricted to the minimum. The alternative is a reliable in vitro model. Human hepatocytes, fresh or cryopreserved are now available commercially. We have successfully produced and identified phase I metabolites from incubations of human hepatocytes with different steroids, such as 17-methyldrostanolone and desoxymethyltestosterone (DMT). The aim of this project is to produce in vitro from human hepatocytes and liver fractions the metabolites of two steroids, the 17-methylated derivatives of stenbolone and its isomer methenolone. The principal metabolites will be synthesized and characterized by NMR and mass spectrometry. The characterization of metabolites will enable the identification of markers of utilization to be incorporated in routine testing methods. The approach for the chemical synthesis of metabolites will be shared with NMI insuring the distribution to other doping control laboratories. Improving the knowledge of steroid biotransformation is a further benefit from these studies. Characterization of 17-Methylstenbolone and 17-Methylmethenolone and Identification of Metabolites Produced by Human Hepatocytes and Liver Fractions WADA Project no. 11A16CA Christiane Ayotte, Philippe Räss, Alexandre Sylvestre, INRS-Institut Armand-Frappier Summary We have synthesized and characterized two designer steroids, 17α-methylmethenolone and 17α- methylstenbolone; the latter is proposed on the internet and two groups have reported different and contradictory results.
    [Show full text]